. 2009 Dec 16;2:9329. doi: 10.1186/1757-1626-2-9329

Table 1.

Trastuzumab use during pregnancy

	Case 1	Case 2	Watson⁵	Fanale⁹	Waterston¹⁰	Bader⁴	Shrim¹¹	Sekar¹²	Witzel¹³	Pant¹⁴
Maternal age	33	38	28	29	30	38	32	28	~32	~33

Stage	IV	III	II	IV	II	IV	IV	IV	IV	IV

Treatment	T	T	T	T/V	T	T/P	T	T/D	T	T

Initiation	2^ndtrimester	Pre	Pre	27/40	Pre	25/40	Pre	23/40	Pre	Pre

Completion	29/40	6/40	20/40	34/40	1/40	28/40	24/40	27/40	NS	30/40

Antenatal complications	None	1 of 2 viable fetal sacs	None	Oligo	None	Anhydramnios "Renal failure"	None	Anhydramnios	Oligo, Vaginal Bleeding	Oligo

Delivery	CS	VD	VD	VD	VD	CS	CS	CS	CS	VD

Gestation	29	39	37.5	34+5	Term	32+1	37	36+2	28	32+1

Perinatal Comp.	Nil	Nil	Nil	Nil	Nil	Fetal distress	Breech	Breech	Bleeding	Nil

Sex	F	F	F	M	F	M	F	M	F	F

Birthweight	1220 g	2940 g	2960 g	2270 g	NS	1460 g	2600 g	2230 g	1015 g	1810 g

Neonatal	RDS	Normal	Normal	Normal	NS	Sepsis, RDS	RDS	Normal	Multiorgan Failure	Normal

Outcome	Nil significant	Normal	Normal	Normal	NS	Normal	Normal	Normal	Neonatal death	Normal

Duration of follow-up	3 years	2 years	6/12	6/12	NS	3/12	2/12	NS	21 weeks	60/12

T = Trastuzumab, V = Vinorelbine, P = Paclitaxel, D = Docetaxel, Pre = Pre-pregnancy, NS = Not stated, Oligo = Oligohydramnios, CS = Caesarean section, VD = Vaginal Delivery, RDS = Respiratory Distress Syndrome